



## PRESS RELEASE

### APPROVAL OF THE CORPORATE EVENTS CALENDAR FOR 2016

Capua, 26 January 2016 – The Board of Directors of Pierrel S.p.A., meeting on the 25 January 2016, has approved pursuant to Article 2.6.2 (*Information requirements*) of the Regulations of the Market that is organised and managed by Borsa Italiana S.p.A. – decided on 10 September 2009 and approved by the CONSOB with its decision no. 17026 of 7 October 2009, as subsequently revised and updated – the calendar of corporate events of Pierrel S.p.A. for 2016, as summarised in the following table.

Date	Event
Week of 7 – 14 April 2016	Board of Directors meeting to approve the draft financial statements for the year ended 31 December 2015
Week of 9 – 13 May 2016	Board of Directors meeting to approve the interim management report for the period ended 31 March 2016
Week of 20 – 27 May 2016	General Meeting of shareholders to approve the financial statements for the year ended December 2015
Week of 22 – 30 August 2016	Board of Directors meeting to approve the abbreviated half-yearly consolidated financial statements at 30 June 2016
Week of 8 – 15 November 2016	Board of Directors meeting to approve the interim management report for the period ended 30 September 2016

The precise date of Directors and shareholders meetings, as well as possible changes to the above, will be communicated to the regulatory authorities and the public in the timeframe and in the manner required by law and applicable regulations.

\* \* \*

**Pierrel S.p.A.** is a global supplier to the pharmaceutical, biopharmaceutical and life science industries, specialising in the discovery of medicinal product candidates and the repositioning of existing drugs for new therapeutic indications and clinical research (TCRDO Division), pharmaceutical production (Contract Manufacturing Division) and the development, registration and licensing of new drugs and medical devices (Pharma Division).

Pierrel Group is listed on the MTA exchange which is organised and managed by Borsa Italiana and boasts over 60 years' experience in the pharmaceutical sector, being one of Europe's leading producers of local and dental anaesthetics. The TCRDO Division, working across Europe and the US, is recognised internationally for its research and development into tech based clinical research innovations with its Drug Repositioning and Repurposing System ("DRR2.0") and Integrated Clinical Development Services ("ICDS") for the pharmaceutical, biotechnology and biomedical industries. The parent company of the TCRDO Division (**THERAMetrics holding AG**, listed in the Swiss stock exchange) holds the innovative interactive **DRR2.0** platform, which runs on a database of 24 million scientific publications (being virtually all of those available in the field of biomedical literature), of over 4,900 drugs and of 9,400 illnesses. With this data, never before collected in one place and stored in the cloud, the Search and Match algorithm can show a researcher not only the candidate drug but also a detailed road map with indications of possible second medical uses. The database can be searched by molecule or by illness.

Pierrel also has a production unit in Capua, close to Naples, Italy, that has been authorised by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) for the aseptic production of



injectable medicines. The subsidiary Pierrel Pharma S.r.l. has registered and distributes the Orabloc® dental anaesthetic in Canada, US, Russia and Europe. The registered office of Pierrel S.p.A. is in Capua (CE), Italy.

**For further information:**

**Pierrel S.p.A.**

*Investor Relations*

Raffaele Petrone

E-mail: [investor.relations@pierrelgroup.com](mailto:investor.relations@pierrelgroup.com)

tel. +39 0823 626 111

fax +39 0823 626 228

**Global Consult s.r.l.**

*Media Relations*

Rossana Del Forno

E-mail: [areacomunicazione@globalconsultsrl.com](mailto:areacomunicazione@globalconsultsrl.com)

tel. +39 333 6178665